Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

UC261

Sigma-Aldrich

(±)-4-Hydroxydebrisoquin sulfate

Synonym(s):

(±)-2-Amidino-4-hydroxy-1,2,3,4-tetrahydroisoquinoline sulfate, (±)-3,4-Dihydro-4-hydroxy-2(1H)-isoquinolinecarboximidamide sulfate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H13N3O · 0.5H2SO4
CAS Number:
62580-84-1
Molecular Weight:
240.27
MDL number:
MFCD09840718
UNSPSC Code:
12161501
PubChem Substance ID:
329827663
NACRES:
NA.77

form

solid

Quality Level

200

color

off-white

mp

267 °C

storage temp.

2-8°C

SMILES string

OS(O)(=O)=O.NC(=N)N1CC(O)c2ccccc2C1.NC(=N)N3CC(O)c4ccccc4C3

InChI

1S/2C10H13N3O.H2O4S/c2*11-10(12)13-5-7-3-1-2-4-8(7)9(14)6-13;1-5(2,3)4/h2*1-4,9,14H,5-6H2,(H3,11,12);(H2,1,2,3,4)

InChI key

AETJLQVZNVTWPH-UHFFFAOYSA-N

Application

(±)-4-Hydroxydebrisoquin sulfate can be used for the metabolic studies of debrisoquin.

Biochem/physiol Actions

CYP2D6 metabolite of debrisoquin.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M J Steiger et al.
Acta neurologica Scandinavica, 86(2), 159-164 (1992-08-01)
Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. There was no significant difference between the proportion of poor metabolisers of DBQ among YOPD patients
Miki Katoh et al.
Journal of pharmaceutical sciences, 96(2), 428-437 (2006-10-20)
We previously clarified that major human drug metabolizing enzymes were expressed in a chimeric urokinase-type plasminogen activator (uPA)+/+/severe combined immunodeficient (SCID) mouse line established recently, in which the liver could be replaced by more than 80% with human hepatocytes. In
A Bozkurt et al.
Journal of pharmaceutical and biomedical analysis, 11(8), 745-749 (1993-08-01)
A simple, selective and sensitive method has been developed to determine debrisoquine and 4-hydroxydebrisoquine in human urine. Separation of the analytes was obtained using a mobile phase of 0.1 M sodium dihydrogen phosphate-acetonitrile (87:13, v/v) and a muBondapak C18 column.
P M Cerqueira et al.
Journal of chromatography. B, Biomedical sciences and applications, 749(2), 153-161 (2001-01-06)
Debrisoquine (D), an antihypertensive drug metabolized to 4-hydroxydebrisoquine (4-OHD) by CYP2D6, is commonly used as an in vivo probe of CYP2D6 activity and can be used to phenotype individuals as either extensive (EMs) or poor metabolizers (PMs) of such drugs
Determination of oxidation phenotype by measurement of propafenone urinary metabolic ratios.
P Lledó et al.
Human & experimental toxicology, 12(2), 161-163 (1993-03-01)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service